Faropenem Sodium: Penem Antibiotic for Broad-Spectrum Research

Executive Summary: Faropenem sodium (CAS No. 122547-49-3) is a non-classical β-lactam antibiotic in the penem class, showing robust efficacy against Gram-positive, Gram-negative, and anaerobic bacteria (APExBIO product profile). It acts through inhibition of bacterial cell wall synthesis via high-affinity binding to penicillin-binding proteins (PBPs) (Oral Faropenem Sodium: AMR Risks). Faropenem sodium is orally bioavailable, with absorption unaffected by food and stability against β-lactamase enzymes. Its use in research is growing, but resistance and regulatory restrictions highlight the necessity for rational application (Faropenem Sodium: Broad-Spectrum Penem Antibiotic for Adv...).

Biological Rationale

Faropenem sodium is part of the penem subclass of β-lactam antibiotics and shares structural similarities with carbapenems, but differs by a sulfur atom at position one. This modification confers increased stability to β-lactamase enzymes produced by resistant bacteria (product information). The compound is effective against diverse pathogens, including Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae, Haemophilus influenzae, Neisseria gonorrhoeae, and anaerobes such as Bacteroides fragilis (Faropenem Sodium: Penem Antibiotic Innovation). It is notable for its ability to inhibit multidrug-resistant and β-lactamase-producing bacteria, making it a preferred agent in advanced infection models where resistance profiling is critical (Faropenem sodium for modern studies).

Mechanism of Action of Faropenem sodium

Faropenem sodium acts by binding to multiple penicillin-binding proteins (PBPs) on bacterial cell membranes, disrupting the final stages of peptidoglycan synthesis and causing cell lysis and death (AMR Risks and Efficacy). Its high affinity for PBPs is responsible for its broad-spectrum bactericidal activity. The compound demonstrates stability against dehydropeptidase-I (DHP-I), allowing for sustained activity in vivo. Unlike many β-lactams, its oral bioavailability is high due to a carrier-mediated absorption system in the small intestine, and food intake does not impact its pharmacokinetics (APExBIO). This property enables flexible experimental designs for in vivo studies on both Gram-positive and Gram-negative bacterial inhibition.

Evidence & Benchmarks

• Faropenem sodium inhibits Staphylococcus spp., Streptococcus spp., and Streptococcus pneumoniae at minimum inhibitory concentrations (MICs) as low as 0.78 μg/mL against clinical isolates (APExBIO).
• It is effective against β-lactamase-producing Haemophilus influenzae and Moraxella catarrhalis, outperforming amoxicillin in in vitro models (Oral Faropenem Sodium: AMR Risks).
• The compound demonstrates broad-spectrum anaerobic activity, with higher efficacy than cefteram, cefixime, and third-generation cephalosporins in comparative assays (Faropenem Sodium: Broad-Spectrum Penem Antibiotic for Adv...).
• Faropenem sodium resists degradation by both β-lactamase and DHP-I, supporting its use in studies of antibiotic resistance mechanisms (Penem Antibiotic Innovation).
• Oral formulations are approved in Japan (since 1997) and India (since 2005); the US FDA and European EMA have not approved clinical use due to concerns about indications and resistance (AMR Risks and Efficacy).
• Pharmacokinetic studies show absorption in the small intestine via a carrier-mediated mechanism, with high serum and interstitial concentrations post-parenteral administration (Npt1-Mediated Renal Transport Mechanism).

Applications, Limits & Misconceptions

Faropenem sodium supports research in antibiotic resistance, inhibition of bacterial cell wall synthesis, and anaerobic bacterial infection models. Its oral bioavailability and broad-spectrum activity enable diverse in vitro and in vivo experimental workflows. APExBIO supplies validated Faropenem sodium (SKU C8712) for laboratory research, ensuring batch-to-batch reproducibility (APExBIO C8712 kit). This article extends the insights in Faropenem sodium for modern studies by providing updated resistance benchmarks and detailing pharmacokinetic nuances for experimentalists.

Common Pitfalls or Misconceptions

• Faropenem sodium is not approved for clinical use in the US or EU, and should not be used outside research contexts (AMR Risks).
• It should not be employed as a first-line agent for routine infections; guidelines recommend its use be restricted to confirmed multidrug-resistant cases (AMR Risks).
• Lack of standardized clinical breakpoints (CLSI/EUCAST) complicates susceptibility testing and interpretation (AMR Risks).
• Overuse can promote cross-resistance to other carbapenems, threatening last-line therapies (AMR Risks).
• Faropenem sodium should be stored sealed and dry at -20°C; long-term storage of solutions is not recommended (APExBIO).

Workflow Integration & Parameters

• Solubility: ≥51.7 mg/mL in DMSO, ≥25.85 mg/mL in ethanol, ≥10.3 mg/mL in water (with ultrasonic assistance) (product profile).
• Storage: Seal and keep dry at -20°C; avoid repeated freeze-thaw cycles. Long-term storage of prepared solutions is discouraged (APExBIO).
• Oral dosing in animal models: Absorption is carrier-mediated and unaffected by food, allowing flexible administration schedules (Npt1-Mediated Transport).
• Resistance profiling: Use in parallel with other β-lactam antibiotics to benchmark MICs and identify cross-resistance patterns (AMR Risks).
• Anaerobic infection models: Faropenem sodium displays superior anaerobe inhibition compared to third-generation cephalosporins (Broad-Spectrum Penem Antibiotic for Adv...).

Conclusion & Outlook

Faropenem sodium is a valuable tool for research on broad-spectrum antimicrobial activity, especially in the context of Gram-positive, Gram-negative, and anaerobic infections. Its unique pharmacokinetic profile and high stability against β-lactamase enzymes support its integration into resistance mechanism studies and infection models. However, rising antimicrobial resistance and lack of clinical breakpoints require careful, rational experimental use. Vigilance against overuse is necessary to prevent cross-resistance with other carbapenems. This article clarifies and updates prior reports such as Faropenem Sodium: Broad-Spectrum Penem Antibiotic for Adv... by emphasizing the latest evidence on resistance trends and workflow parameters.